Ionophore reverses Alzheimer's within days in mouse models

Jul 09, 2008

Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).

Recent research has implicated dysregulation of metal ions in the brain, particularly copper and zinc, in the pathogenesis of AD and the damaging accumulation of amyloid beta (A?) protein that is characteristic of this devastating disease. The ionophore clioquinol (CQ), an 8-hydroxyquinoline, has been shown to increase intracellular copper and zinc levels and decrease A? levels in cultured cells and in the brains of transgenic (Tg) AD mice. However, further studies in mice and humans demonstrated that brain entry of CQ was quite limited.

Dr. Ashley I. Bush from the Mental Health Research Institute of Victoria in Australia, with Dr. Paul A. Adlard and colleagues examined the therapeutic potential of PBT2, a second generation 8-hydroxyquinoline designed for easier synthesis, higher solubility and increased blood-brain barrier permeability, in two well established Tg mouse models of AD. The Tg mice examined in the study overexpress the precursor protein for A? and possess mutations that cause AD in humans. One of the Tg models also expresses the human presenilin deletion mutation that also causes AD.

"Both types of Tg mice exhibit progressive spatial learning deficits that are accompanied by increasing A? levels and plaque formation. Demonstrating benefits of PBT2 treatment in the two separate models was both a stringency test, increasing confidence that PBT2 is more likely to show benefit in clinical trials, and also allowed us to determine whether specific forms of A? change in register with cognitive improvement in both strains. This is significant as cognitive loss in AD is not just a simple product of rising A? levels," explains Dr. Bush.

PBT2 was shown to be a superior ionophore when compared to CQ and the researchers went on to test A? levels and cognitive outcomes after oral treatment with PBT2. "We found that oral treatment with PBT2 induced a dramatic improvement in learning and memory in both Tg models of AD, accompanied by a marked inhibition of AD-like neuropathology. These outcomes were rapid, with reduction of soluble interstitial A? occurring within hours, and significant cognitive benefits seen within days of first administration of the compound," says Dr. Bush.

These results encourage further testing of compounds that target synaptic metals as a possible treatment of AD. Further, recent clinical trials in AD patients taking oral PBT2 have been promising and support PBT2 as a viable treatment for AD.

Source: Cell Press

Explore further: Lessons learned six months into worst Ebola outbreak

add to favorites email to friend print save as pdf

Related Stories

Big new iPhone brings Apple more profit

3 hours ago

Apple's largest iPhone is selling for $100 more than its other new model, but a new report says it costs Apple only $15.50 more to make the more expensive version.

Being sheepish about climate adaptation

4 hours ago

For thousands of years, man has domesticated animals, selecting the best traits possible for survival. Now, livestock such as sheep offer an intriguing animal to examine adaptation to climate change, with a genetic legacy ...

Recommended for you

Chikungunya fever identified in the United States

3 hours ago

(HealthDay)—Chikungunya fever is being seen in travelers returning to the United States from affected regions and should be considered as a diagnosis for febrile travelers, according to an ideas and opinions ...

Boost in quest for TB breath test

5 hours ago

A simple breath test may one day show whether someone has a strain of tuberculosis that will respond to a frontline antibiotic, or a drug-resistant type, scientists said Tuesday.

Three more dead from Legionnaire's disease in Spain

5 hours ago

Three more people have died from Legionnaire's disease in Catalonia in northeastern Spain, officials said Tuesday, bringing to seven the death toll from the lung infection in the region in just over a week.

User comments : 0